478183-60-7

Basic information

• Product Name: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid
• Synonyms: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid;Boc-(S)-2-aMino-3-cyclobutylpropanoic acid;Boc-(S)-3-Cyclobutylalanine;(Tert-Butoxy)Carbonyl (S)-3-Cyclobutylalanine;Boc-L-Cyclobutylalanine DIPA;N-Boc-S-Cyclobutylalanine
• CAS NO: 478183-60-7
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Mol File: 478183-60-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(478183-60-7)
• EPA Substance Registry System: (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid(478183-60-7)

Safety Data

• Hazardous Substances Data: 478183-60-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid serves as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure, including the Boc protecting group and cyclobutyl moiety, allows for the creation of complex molecules with specific biological activities, contributing to the development of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid is utilized as a versatile building block for the assembly of a wide range of biologically active compounds. Its presence of a carboxylic acid group facilitates further reactions and modifications, enabling the synthesis of diverse chemical entities with potential applications in medicine, agrochemicals, and other areas.
Used in Research and Development:
(S)-2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid is also employed in research and development settings, where its reactivity and structural features are explored to understand its potential in creating new chemical entities. Its stability and ease of handling make it an attractive candidate for studies aimed at uncovering new reactions and applications in synthetic chemistry.

Upstream product

• 4415-82-1 cyclobutanemethanol 
• 1201593-65-8 (S)-2-amino-3-cyclobutylpropanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 16408-62-1 cyclobutylmethyl iodide 

Downstream Products

• 918662-56-3 [2-cyclobutyl-1S-(methoxymethylcarbamoyl)ethyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.